Business Wire

STORFUND

29.6.2022 09:02:06 CEST | Business Wire | Press release

Share
Senior Worldfirst Executive Joins UK Fintech Storfund

After a six month search, Storfund has appointed Worldfirst’s former Global Head of Enterprise, Oliver Whelan, as its Chief Revenue Officer. Whelan, who spent almost a decade at payments fintech Worldfirst, will be responsible for accelerating Storfund’s rapid and profitable growth.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220629005094/en/

Available in 20 countries on the world’s biggest marketplaces, including Cdiscount, Back Market, PcComponentes, Fyndiq and Amazon, Storfund is one of the UK’s fastest growing fintechs. But what’s more remarkable in an industry obsessed with scaling loss-making operations, Storfund has achieved this growth whilst turning a profit.

The founders took the decision to fund growth from revenue rather than external capital, believing this would create an impact-driven culture: growth would only come if clients saw that its service was worth paying for.

“Unlike its competitors, Storfund has focused on its product and, most importantly, its customers” said Whelan, “it knows why it exists and it hasn’t forgotten this in the pursuit of growth.” Storfund is the only European provider of factoring - immediate payment on sales - to marketplace sellers, an essential service given businesses wait 42 days on average to get paid.

“Cashflow remains the biggest challenge for ecommerce businesses,” said Whelan. “There are a few start-ups offering loans to ecommerce sellers, but Storfund is still the only European fintech to offer working capital in the form of factoring. Traditional banks, even digital challenger banks, still don’t understand the ecommerce sector.”

“Storfund’s potential is immense” said Whelan, “it is offering a simple solution to an industry worth almost £4 trillion.”

Demand for its service means that Storfund has doubled the financing it provides every year for the past three years; and last autumn Storfund announced that it had put in place financing which would enable it to provide up to £5 billion each year to ecommerce businesses. Whelan’s task will be to capitalise on this momentum, drawing on his experience at Worldfirst.

Worldfirst’s breakneck growth saw it transfer over £70 billion for customers between its launch in 2004 and 2019 when it was acquired by Ant Group, in one of the largest deals by the world’s largest fintech. As Wordfirst’s Global Head of Enterprise, Whelan was responsible for negotiating the business’s largest strategic ecommerce and financial partnerships.

“Worldfirst’s success was driven by its culture,” said Whelan, “and Storfund is the same. It has a fantastic team and loyal, enthusiastic customers – over a third of new business comes from recommendations”.

“The strength of our product, our funding structure and obsession with profitable growth enables us to stay 100% focused on our mission, said George Brintalos, CEO and co-founder, “it’s also one of the reasons we are able to attract exceptional talent like Oliver and continue to hire whilst the industry as a whole is retrenching.”

The tech industry has been awash with venture capital over the past three years, and Storfund’s unusual decision not to take external capital puts it in a strong position to weather the market downturn, which has particularly affected the value of tech businesses. Without the pressure for returns, Storfund is well placed to continue growing via steady expansion.

The next few years will be all about expansion through partnerships with fast-growing marketplaces across Europe, Asia and the Americas. “Oliver is the right person at the right time,” said Akbar Ahsan, co-founder, “not only does he have an enviable track record and a vast network, he’s also the right cultural fit. He has an entrepreneurial mindset and gets our mentality of rolling your sleeves up and getting stuck-in, but he also brings the discipline and process-driven thinking that large corporations instil, which will be crucial as our international operations expand even further.”

Whelan’s appointment follows Storfund’s strategy of appointing experienced ecommerce executives to senior roles. Other notable hires include David Rolls from Amazon and Margaret-Anne Galvin from Cdiscount.

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release

A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release

Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye